炎症性肠病与乳糜泻关联的系统综述与荟萃分析
该系统综述与荟萃分析检索多个数据库至2019年6月25日,纳入65项研究,评估炎症性肠病(IBD)与乳糜泻(CeD)的关联。中等确定性证据显示,IBD患者对比对照的CeD风险升高(RR 3.96;95%CI 2.23-7.02),CeD患者对比对照的IBD风险升高(RR 9.88;95%CI 4.03-24.21)。
要点
- IBD患者发生乳糜泻的风险约为对照的3.96倍(中等确定性证据)。
- 乳糜泻患者发生IBD的风险约为对照的9.88倍(中等确定性证据)。
- 需高质量前瞻性队列研究评估IBD与CeD特异性生物标志物风险。
核心结论
- 与对照人群相比,乳糜泻患者中IBD风险升高,IBD患者中乳糜泻风险也升高。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、EMBASE、CENTRAL、Web of Science、CINAHL、DARE和SIGLE至2019年6月25日,最终纳入65项研究。
主要发现
- IBD患者对比对照的乳糜泻风险升高,RR 3.96(95%CI 2.23-7.02),为中等确定性证据。
- 乳糜泻患者对比对照的IBD风险升高,RR 9.88(95%CI 4.03-24.21),为中等确定性证据。
- 乳糜泻患者对比对照的抗酿酒酵母抗体风险升高,RR 6.22(95%CI 2.44-15.84),为低确定性证据。
- IBD患者对比对照的HLA-DQ2或DQ8风险无差异,RR 1.04(95%CI 0.42-2.56),为低确定性证据。
关键数值与推荐
- 采用Newcastle-Ottawa量表评估偏倚风险,采用GRADE评估证据确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: There is controversy over the association between celiac disease (CeD) and inflammatory bowel diseases (IBD). We performed a systematic review and meta-analysis to assess evidence for an association between CeD and IBD. METHODS: We searched databases including MEDLINE, EMBASE, CENTRAL, Web of Science, CINAHL, DARE, and SIGLE through June 25, 2019 for studies assessing the risk of CeD in patients with IBD, and IBD in patients with CeD, compared with controls of any type. We used the Newcastle-Ottawa Scale to evaluate the risk of bias and GRADE to assess the certainty of the evidence. RESULTS: We identified 9791 studies and included 65 studies in our analysis. Moderate certainty evidence found an increased risk of CeD in patients with IBD vs controls (risk ratio [RR] 3.96; 95% confidence interval [CI] 2.23-7.02) and increased risk of IBD in patients with CeD vs controls (RR 9.88; 95% CI 4.03-24.21). There was low-certainty evidence for the risk of anti-Saccharomyces antibodies, a serologic marker of IBD, in patients with CeD vs controls (RR 6.22; 95% CI 2.44-15.84). There was low-certainty evidence for no difference in risk of HLA-DQ2 or DQ8 in patients with IBD vs controls (RR 1.04; 95% CI 0.42-2.56), and very low-certainty evidence for an increased risk of anti-tissue transglutaminase in patients with IBD vs controls (RR 1.52; 95% CI 0.52-4.40). Patients with IBD had a slight decrease in risk of anti-endomysial antibodies vs controls (RR 0.70; 95% CI 0.18-2.74), but these results are uncertain. CONCLUSIONS: In a systematic review and meta-analysis, we found an increased risk of IBD in patients with CeD and increased risk of CeD in patients with IBD, compared with other patient populations. High-quality prospective cohort studies are needed to assess the risk of CeD-specific and IBD-specific biomarkers in patients with IBD and CeD.
引用
- Pinto-Sanchez MI, Seiler CL, Santesso N, et al. Association Between Inflammatory Bowel Diseases and Celiac Disease: A Systematic Review and Meta-Analysis. Gastroenterology. 2020. PMID: 32416141. doi:10.1053/j.gastro.2020.05.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。